Genocea Biosciences (GNCA) Reports Evidence of Long Lasting Immune Activity in GEN-009 Treated Patients
Tweet Send to a Friend
Needham & Company analyst Gil Blum reiterated a Buy rating and $6.00 price target on Genocea Biosciences (NASDAQ: GNCA) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
